To assess the therapeutic implications of ORMDL2 dysregulation in GBM, we conducted pharmacogenomic analyses was conducted using the Genomics of Drug Sensitivity in Cancer (GDSC) and Cancer Therapeutics Response Portal (CTRP) datasets. Here, ORMDL2 is linked to glioblastoma.